阿片类药物治疗慢性非癌性疼痛:系统综述与荟萃分析
与安慰剂相比,阿片类药物对疼痛和躯体功能有统计学显著但幅度较小的改善,并增加呕吐风险;与非阿片类药物相比,获益可能相似但证据质量低至中等。
要点
- 与安慰剂相比,阿片类药物降低疼痛0.69 cm(95%CI -0.82至-0.56),改善躯体功能2.04分(95%CI 1.41至2.68)。
- 阿片类药物呕吐发生率为5.9%,安慰剂为2.3%(排除导入期不良事件患者的试验)。
- 与非阿片类药物相比疼痛和功能获益可能相似,但证据质量仅为低至中等。
核心结论
- 高质量研究证据显示阿片类药物对慢性非癌性疼痛的疼痛和躯体功能有统计学显著但幅度较小的改善,并增加呕吐风险。
- 与非阿片类药物相比,阿片类药物对疼痛和功能的获益可能相似,但证据来自低至中等质量研究。
研究设计与样本
- 系统综述与荟萃分析,检索CENTRAL、CINAHL、EMBASE、MEDLINE、AMED和PsycINFO从建库至2018年4月的随机临床试验。
- 纳入试验包括25项神经病理性疼痛、32项伤害性疼痛、33项中枢敏化(无组织损伤的疼痛)和6项混合类型疼痛试验。
- 采用随机效应模型和GRADE系统评价证据质量。
主要发现
- 与安慰剂相比,阿片类药物降低疼痛加权均数差为-0.69 cm(95%CI -0.82至-0.56 cm,10 cm视觉模拟量表),达到最小重要差异的模型风险差为11.9%(95%CI 9.7%至14.1%)。
- 与安慰剂相比,阿片类药物改善躯体功能加权均数差为2.04分(95%CI 1.41至2.68分,100分SF-36躯体成分评分),达到最小重要差异的模型风险差为8.5%(95%CI 5.9%至11.2%)。
- 在排除导入期不良事件患者的试验中,阿片类药物呕吐发生率为5.9%,安慰剂为2.3%。
- 与NSAIDs相比,阿片类药物对疼痛的WMD为-0.60 cm(95%CI -1.54至0.34 cm),对躯体功能的WMD为-0.90分(95%CI -2.69至0.89分)。
- 与三环类抗抑郁药相比,阿片类药物对疼痛的WMD为-0.13 cm(95%CI -0.99至0.74 cm),对躯体功能的WMD为-5.31分(95%CI -13.77至3.14分)。
关键数值与推荐
- 疼痛主要结局采用0-10 cm视觉模拟量表,评分越低越好,最小重要差异为1 cm。
- 躯体功能主要结局采用0-100分SF-36躯体成分评分,评分越高越好,最小重要差异为5分。
- 呕吐为主要结局之一,在排除导入期不良事件患者的试验中阿片类药物组为5.9%,安慰剂组为2.3%。
临床怎么用
- 阿片类药物对慢性非癌性疼痛的疼痛和功能改善幅度较小,临床决策需权衡获益与呕吐等风险。
- 与非阿片类药物相比阿片类药物的获益可能相似,可考虑非阿片类药物作为替代选择,但需注意证据质量低至中等。
局限性
- 与非阿片类药物比较的证据仅来自低至中等质量研究。
- 呕吐发生率数据来自排除导入期不良事件患者的试验,可能影响代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Harms and benefits of opioids for chronic noncancer pain remain unclear. OBJECTIVE: To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain. DATA SOURCES AND STUDY SELECTION: The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control. DATA EXTRACTION AND SYNTHESIS: Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence. MAIN OUTCOMES AND MEASURES: The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting. RESULTS: Ninety-six RCTs including 26 169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], -0.69 cm [95% CI, -0.82 to -0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, -0.60 cm [95% CI, -1.54 to 0.34 cm]; physical functioning: WMD, -0.90 points [95% CI, -2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, -0.13 cm [95% CI, -0.99 to 0.74 cm]; physical functioning: WMD, -5.31 points [95% CI, -13.77 to 3.14 points]), and anticonvulsants (pain: WMD, -0.90 cm [95% CI, -1.65 to -0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, -5.77 to 6.66 points]). CONCLUSIONS AND RELEVANCE: In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality.
引用
- Busse JW, Wang L, Kamaleldin M, et al. Opioids for Chronic Noncancer Pain: A Systematic Review and Meta-analysis. JAMA. 2018. PMID: 30561481. doi:10.1001/jama.2018.18472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。